June 17-22, 2018
Fairmont Tremblant
Mont Tremblant, Quebec, Canada
| Editors: | Amine Kamen, McGill University |
|---|---|
| Tarit Mukhopadhyay, University College London | |
| Nathalie Garcon, Bioaster | |
| Charles Lutsch, Sanofi Pasteur |
The articles for these proceedings are not peer-reviewed.
Conference Program, Amine Kamen, Tarit Mukhopadhyay, Charles Lutsch, and Nathalie Garçon (Article)
The impact of vaccines worldwide and the challenges to achieve universal immunization, Alejandro Cravioto (Abstract)
Structure-based vaccines for respiratory viruses, Barney Graham (Abstract)
mRNA Vaccines: On the progress from promise to reality, Hari Pujar (Abstract)
RNActive®-An mRNA-based vaccine technology for next generation prophylactic vaccines, Edith Jasny (Abstract)
Virus-like particle vaccines against BK and JC polyomaviruses, Diana V. Pastrana, Alberto Peretti, Eileen M. Geoghegan, and Christopher B. Buck (Abstract and Presentation)
Molecular quality engineering for low cost vaccine production, Kerry Routenberg Love, Neil C. Dalvie, J. Christopher Love, and Joseph R. Brady (Abstract)
Single-cell analysis uncovers a novel influenza A virus-derived defective interfering particle for antiviral therapy, Sascha Young Kupke, Dietmar Riedel, Timo Frensing, Pawel Zmora, and Udo Reichl (Abstract)
Persistent antibody clonotypes dominate the serum response to influenza following repeated vaccination over multiple years, Jiwon Lee; Andrew P. Horton; Jonathan R. McDaniel; Daniel R. Boutz; Jiwon Jung; Dania A. Hussein; Gregory C. Ippolito; George Georgiou; Philipp Paparoditis,; Alexander Frühwirth; Leontios Pappas; Davide Corti; and Antonio Lanzavecchia (Abstract)
Pan-HA antibodies confer protection in mice against influenza, Aziza Manceur, Wangxue Chen, Amalia Ponce, Anne Marcil, Wei Zou, Gilles St-Laurent, Yves Durocher, Mélanie Leclerc, Parminder Chahal, Sven Ansorge, Marie-Hélène Venne, Viktoria Lytvyn, and Rénald Gilbert (Abstract)
The story of a successful biotech (ad)venture: The development of Flublok, Manon Cox (Abstract)
Accelerating bioprocess development by analysis of all available data: A USP case study, Diego Suarez-Zuluaga, Nicole Driessen, Yvonne Thomassen, Wilfried Bakker, and Daniel Borchert (Abstract)
Purifying viruses with a sheet of paper: Single-use steric exclusion chromatography as a capture platform for vaccine candidates, Pavel Marichal-Gallardo, A. Raquel Fortuna, Yvonne Genzel, Michael Wolff, and Udo Reichl (Abstract)
Vero SF technology platform: Strategy for rapid and effective vaccine development; flavivirus vaccines case study, Nicolas Sève, Anne-marie Beauchard, and Jean-Marc Guillaume (Abstract)
Bioprocess intensification for production of a Peste des petits ruminants virus (PPRV) vaccine, Manuel J.T. Carrondo, Marcos Sousa, Gerhard Greller, Christel Fenge, Jens Rupprecht, and Alexander Tappe (Abstract)
Developing vaccines for low resource settings through product development partnerships (PDPs), David Kaslow (Abstract)
Continuous purification of cell culture-derived influenza A virus particles through pseudo- affinity membrane chromatography, A. Raquel Fortuna, Florian Taft, Louis Villain, Michael W. Wolff, and Udo Reichl (Abstract)
Integrated scalable cyto-technology for recombinant protein bioprocessing, J. Christopher Love, Amos Lu, Kerry R. Love, and Laura Crowell (Abstract)
Low-cost cell-based production platform for seasonal and pandemic influenza vaccines, Alan Yung-Chih Hu, Tsai-Chuan Weng, Jenny Bang, and Jessie H.-T. Ni (Abstract)
Polymer grafted chromatography media for direct capture and high-resolution purification of enveloped virus-like particles, Patricia Pereira Aguilar, Tobias A. Schneider, and Alois Jungbauer (Abstract)
Virus-like particles (VLPs) as a platform for the development of yellow fever and Zika virus vaccine candidate, Renata Alvim and Leda R. Castilho (Abstract)
Manufacturing strategies for sustainable supply of ultra-low cost vaccines for global health, Tania Pereira Chilima, Laura Crowell, J. Christopher Love, Tarit Mukhopadhyay, and Suzanne S. Farid (Abstract)
A tailor-made purification strategy for oncolytic measles viruses using membrane-based processes, Daniel Loewe, Tanja A. Grein, Tobias Weidner, Denise Salzig, Peter Czermak, and Hauke Dieken (Abstract)
Formulation considerations for the development of adjuvanted vaccines, Jean Haensler, Director (Abstract)
Intradermal administration of synthetic DNA vaccines induce robust cellular and humoral immune responses, Jean D. Boyer (Abstract)
Thermostabilization of adenovirus-vectored vaccines, removing the need for continual cold-chain storage, Alexander Douglas, Pawan Dulal, Rebecca Ashfield, Adam Ritchie, Katarzyna Kowal, Stephen Russell, Steven Neil, Josine Wilmer, Anna Stedman, and George Warimwe (Abstract)
Safety and biodistribution of sulfated archaeal glycolipid archaeosomes as vaccine adjuvants, Mike McCluskie, Felicity C. Stark, Yimei Jia, Umar Iqbal, Lise Deschatelets, Renu Dudani, Blair Harrison, Lakshmi Krishnan, and Michael J. McCluskie (Abstract)
Recombinant hemagglutinin proteins formulated in a novel PELC/CpG adjuvant for H7N9 subunit vaccine development, Suh-Chin Wu, Ting-Hsuan Chen, Ying-Yu Liu, Maureen Spearman, Michael Butler, Jia-Tsrong Jan, and Ming-Hsi Huang (Abstract)
Accelerated process development and stockpile for MERS, LASSA AND NIPAH viral vaccine, Simone Blayer, Karianne Johansen, Gunnstein Norheim, and Melanie Saville (Abstract)
Rapid response pipeline for stabilized subunit vaccines, Keith Chappell, Daniel Watterson, and Paul Young (Abstract)
Using the AdVac® vaccine manufacturing platform for rapid response to infectious disease outbreaks, Guus Erkens (Abstract)
Preclinical development of filovirus and flavivirus vaccines based on recombinant insect cell expressed subunits, Axel T. Lehrer, Teri-Ann S. Wong, Michael M. Lieberman, Liana O. Medina, and Thomas Geisbert (Abstract)
Development of Pan-filovirus vaccine against Ebola and Marburg virus challenges, Xiangguo Qiu, Md Niaz Rahim, Edmund G. Wee, Shihua He, Jonathan Audet, Bette M. Korber, and Tomáš Hanke (Abstract)
High-titer rapid response platform for epidemic preparedness, José Castillo (Abstract and Presentation)
Vaccines for poverty. Associated infection diseases: Accessing innovation, Jerome Kim (Abstract)
Future prospects and application for the development of adenovirus-based vaccine, Tao Zhu and Xuefeng Yu (Abstract)
Adjuvant manufacturing scale-up and technology transfer, Christopher Fox (Abstract)
A vaccine for Ebola virus – approaches and results of accelerated process development and characterization studies, Randi Saunders, Joseph P Califano, Dusan Ruzic, and Kristin Valente (Abstract and Presentation)
Product development and programmatic implementation of TYPBAR TCV® and ROTAVAC® vaccines, V. K. Srinivas (Abstract)
A novel vaccinia virus backbone for the delivery of immunotherapeutic genes, John Bell (Abstract)
HER2 cancer vaccine optimization by combining Drosophila S2 insect cell manufacturing with a novel VLP-display technology, Thomas Jørgensen, Max Soegaard, Arianna Palladini, Susan Thrane, Christoph M Janitzek, Jessica Pihl, Thomas M. Clausen, Morten A. Nielsen, Thor G. Theander, Giordano Nicoletti, Lorena Landuzzi, Tania Balboni, Marianna L. Ianzano, Veronica Giusti, Pier-Luigi Lollini, Patrizia Nanni, Adam F. Sander, and Willem A. de Jongh (Abstract)
Rapid design/development and clinical deployment of synthetic DNA vaccine technology for difficult immune targets, David Weiner (Abstract)
Development of an analytical platform for delivery of recombinant oncolytic viruses, Gautam Sanyal (Abstract)
Leveraging vectored vaccine candidates manufacturing to GMP compatible bioprocesse, Cristina Peixoto, Faria T, Carrondo MJT, Tomás HA, Rodrigues AF, Moleirinho M, Coroadinha AS, and Alves PM (Abstract)
Purification of flavivirus VLPs by a two-step chromatographic process, Matheus Souza and Leda R. Castilho (Abstract)
Flavivirus production in perfusion processes using the EB66® cell line, Alexander Nikolay, Arnaud Léon, Klaus Schwamborn, Yvonne Genzel, and Udo Reichl (Abstract)
Production and characterization of HER2-displaying budded virus-like particles and their potential as cancer vaccines, Lisa Nika, Guha Asthagiri Arunkumar, Sara Cuadrado, Florian Krammer, and Reingard Grabherr (Abstract)
Virus-like particles: A flexible platform for universal influenza vaccine development, Sarah Slack, Jonathan Welsh, Lucy Foley, and Tarit Mukhopadhyay (Abstract)
Rapid virus titration using flow cytometry, Steve George and Patrick Farrell (Abstract)
Defining the multiplicity and type of infection for the production of Zaire Ebola virus-like particles in the insect cell baculovirus expression system, Ana Ruth Pastor, Carlos F. Arias, Alejandro Alagón, Octavio T. Ramírez, Laura A. Palomares, and Gonzalo González-Domínguez (Abstract)
Combining novel and traditional approaches of vaccine development to overcome the challenges of first-in-human trial for Group A Streptococcus, Elodie Burlet, Garry Morefield, Anisa Dunham, and Harm HogenEsch (Abstract)
Development of suspensions adapted Vero cell culture process for production of viruses, Chun Fang Shen, Claire Guilbault, Mehdy Elahi, Sven Ansorge, Lakshmi Krishnan, Rénald Gilbert, Xiuling Li, and Amine Kamen (Abstract and Presentation)
A pre-fusion, trimeric subunit influenza HA-based vaccine elicits cross-protection between highly divergent influenza A viruses, Christopher McMillan, Keith Chappell, Stacey Cheung, Daniel Watterson, Kirsty Short, and Paul Young (Abstract)
HER1 therapeutic cancer vaccine: An active immunotherapy treatment for patients with tumors expressing the receptor of epidermal growth factor (EGF-R), Eduardo Suarez, Zaima Mazorra, Diana R. Hernández, Narjara González, Anabel Labastida, Yaima Ramírez, and Belinda Sánchez (Abstract)
Production of bacterial outer membrane vesicles as vaccine platform, Matthias Gerritzen, Merijn L.M. Salverda, Dirk E. Martens, René H. Wijffels, Peter van der Ley, and Michiel Stork (Abstract)
Extended gene expression for HIV-1 VLPs scale-up and production enhancement using shRNA and chemical additives, Laura Cervera Gracia, Javier Fuenmayor, Francesc Gòdia, Irene Gonzalez-Domínguez, and Francesc Gòdia (Abstract)
Development of scalable manufacturing process and GMP-compatible formulation for a novel recombinant schistosomiasis vaccine, Damon R. Asher, Bart Fryszczyn, Jeffrey Shumway, Claire Scanlan, Elissa Hudspeth, Maria Elena Bottazzi, Patrick McAtee, Jeroen Pollet, and Chris Seid (Abstract)
Innovations in global health: What has been accomplished, what is on the horizon and where are more investments needed, David Robinson (Abstract)
Stability evaluation of inactivated influenza H7N9 vaccines derived from adhesion and suspension MDCK cells, Alan Yung-Chih Hu, Tsai-Teng Tzeng, Min-Shi Lee, and Chia-Chun Lai (Abstract)
Rapid, cost-effective and scalable gmp-compliant simian adenovirus-vectored vaccine production for early-phase clinical trials using entirely disposable product-contact components, Alexander Douglas, Thomas Merritt, Sofiya Fedosyuk, Adam Ritchie, Phillip Angell-Manning, Sarah Gilbert, and Alex Xenopoulos (Abstract)
Flavivirus production in perfusion processes using the EB66® cell line, Alexander Nikolay, Yvonne Genzel, Klaus Schwamborn, Arnaud Léon, and Udo Reichl (Abstract)
Latest advancements in process intensification to support global demand for affordable vaccines, Alfred Luitjens, Chris Yallop, and Batavia Biosciences (Abstract)
Proteomic characterization of influenza H1N1 Gag virus-like particles and extracellular vesicles produced in HEK-293SF, Alina Venereo-Sanchez, Amine Kamen, Kelly Fulton, Olivier Henry, and Susan Twine (Abstract)
Implementation of a process-scale adenovirus purification with a single-use platform, Amélie Boulais, Miyako Hirai, Maria Mellado, and Cristina Peixoto (Abstract)
Membrane chromatography cassettes for bind and elute applications of viruses and large proteins, Stefan Fischer-Frühholz, Martin Leuthold, Stefan Weisshaar, Florian Taft, Miyako Hirai, and Amélie Boulais (Abstract and Presentation)
Influenza virus capture using membrane chromatography: Improving selectivity by matrix design and pseudo-affinity ligand interactions, Stefan Fischer-Frühholz, Florian Taft, Louis Villain, Amélie Boulais, R. Köhler, Sebastian van Teeffelen, Michael W. Wolff, Udo Reichl, and A. Raquel Fortuna (Abstract and Presentation)
Defining the multiplicity and type of infection for the production of Zaire Ebola Virus-like particles in the insect cell baculovirus expression system, Ana Ruth Pastor, Gonzalo González-Domínguez, Carlos F. Arias, Alejandro Alagón, Octavio T. Ramírez, and Laura A. Palomares (Abstract)
Structure-based vaccine design by electron microscopy, Anette Schneemann, Jeffrey A. Speir, Travis Nieusma, Mandy Janssen, Sarah Dunn, Nicole Chiang, Anchi Cheng, Thejusvi Ganesh, Sargis Dallakyan, Bridget Carragher, and Clinton S. Potter (Abstract)
Reducing risks with a serum-free medium for MRC-5 based vaccine production, Anna-Barbara Hachmann, Andrew M. Campbell, and Jennifer Donato (Abstract)
Process economical effects of implementation of ready-to-use micro carriers in cell- based virus vaccine production, Nicolas Seve, Landry Bertaux, Nicolas Seve, and Jean-Marc Guillaume (Abstract)
Bioprocess engineering of insect cells for accelerating vaccines development, Antonio Roldao, Manuel Carrondo, Paula Alves, Ana Teixeira, Cristina Peixoto, Ricardo Correia, João Vidigal, and Barbara Fernandes (Abstract)
A scalable adenovirus production process, from cell culture to purified bulk, Åsa Hagner-McWhirter, Gustaf Ahlén, Magnus Bergman, Mats Lundgren, Åsa Lagerlöf, Anna Åkerblom, Elisabeth Wallby, Sravani Musunuri, Maria Soultsioti, Pelle Sjöholm, Sara Häggblad-Sahlberg, and Eva Blanck (Abstract)
Vaccine protein stabilization in silica, Aswin Doekhie, Asel Sartbaeva, and Jean van den Elsen (Abstract)
Experimental and computational fluid dynamics studies of adherent cells on microcarriers in an ambr® 250 bioreactor, Barney Zoro, Ned Grace, A. Neil Bargh, John P. J. Betts, Marco C. Rotondi, Alvin W. Nienow, Mariana P. Hanga, Christopher J. Hewitt, and Qasim A. Rafiq (Abstract)
From bench scale to pilot plant operation: Business models and challenges in the biopharmaceutical industry in Brazil, Beatriz de Castro Fialho, Caride Elena, Freire Marcos, and Gaspar Luciane (Abstract)
Immunization with Fc-based recombinant Epstein-Barr virus gp350 elicits potent neutralizing humoral immune response in a BALB/c mice model, Bing-chun Zhao, Lin Feng, Ling Gao, Musheng Zeng, Haojiong Zhang, Miao Xu, Yixin Zeng, Xiao Zhang, Claude Krummenacher, Shuo Song, and Yuting Xu (Abstract)
Strategies to overcome the age-old problem of immunosenescence, Brian Schanen (Abstract)
Development and validation of a proprietary medium formulation for recombinant subunit vaccines by the Baculovirus Expression Vector System (BEVS), Catherine Cleuziat,; Sophie Biard; Chloé Damiany; Sylvain Lagresle; Christine Coupier; Amine Kamen; Hervé Poulet; Noël Detraz; Zahia Hannas; Géraldine Popovic; Chun Fang Shen; and Amine Kamen (Abstract)
Development of an animal-component free insect medium for the Baculovirus Expression Vector System (BEVS), Catherine Cleuziat, Catherine Cushny, Lu Chen, Jessie H.-T. Ni, and Jenny Y. Bang (Abstract)
How to limit the use of serum in viral processes: A gibco perspective, Céline Martin, Margarito Rojas, Serena Fries Smith, Abhijeet Kohli, and Steve Gorfien (Abstract)
A pre-fusion, trimeric subunit influenza HA-based vaccine elicits cross-protection between highly divergent influenza A viruses, Christopher McMillan, Keith Chappell, Kirsty Short, Daniel Watterson, Paul Young, and Stacey Cheung (Abstract)
Superinfection arising in stable lentiviral vector producer cell lines bearing Cocal-G envelope proteins, Christopher Perry, Yasu Takeuchi, Tarit Mukhopadhyay, Maha Tijani, and Altar Munis (Abstract)
Development of suspensions adapted Vero cell culture process for production of viruses, Chun Fang Shen, Mehdy Elahi, Sven Ansorge, Lakshmi Krishnan, Rénald Gilbert, Claire Guilbault, Xiuling Li, and Amine Kamen (Abstract)
Addressing the challenges of influenza virus-like particles purification, Cristina Peixoto, Sofia B. Carvalho, Manuel J.T. Carrondo, Paula M. Alves, A. Raquel Fortuna, Udo Reichl, and Michael Wolff (Abstract)
A genome-wide CRISPR screen to generate high-yield cell lines for pandemic influenza vaccine production, David M. Sharon and Amine Kamen (Abstract)
Process development for a flexible vaccine vector platform based on recombinant life virus, Dieter Palmberger, Petra Steppert, Alois Jungbauer, and Gerald Striedner (Abstract)
HER1 therapeutic cancer vaccine: An active immunotherapy treatment for patients with tumors expressing the receptor of epidermal growth factor (EGF-R), Eduardo Suarez, Belinda Sánchez, Zaima Mazorra, Diana R. Hernández, Narjara González, Anabel Labastida, and Yaima Ramírez (Abstract)
Combining novel and traditional approaches of vaccine development to overcome the challenges of first-in-human trial for Group A Streptococcus, Elodie Burlet, Anisa Dunham, Garry Morefield, and Harm HogenEsch (Abstract)
Accelerated mass production of influenza virus seed stocks in HEK-293 suspension cell cultures by reverse genetics, Ernest Milián, Rafael Biaggio, Alina Venereo-Sanchez, Thomas Julien, Manuel Rosa-Calatrava, Emma Petiot, Amine Kamen, Johnny Montes, Sven Ansorge, Aziza P. Manceur, and Danielle Jacob (Abstract)
Implementation of a strategy to produce a broadly neutralizing monoclonal antibody against Zika and dengue viruses, Esmeralda Cuevas-Juárez and Laura A. Palomares (Abstract)
Optimization of a flocculation step using a scale-down model with 3D-printed impellers and Focused Beam Reflectance Measurement (FBRM) particle-size monitoring, Francis DiGennaro (Abstract)
Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice, Guha Asthagiri Arunkumar, Florian Krammer, Meagan McMahon, Vincent Pavot, Mario Aramouni, Sarah Gilbert, and Teresa Lambe (Abstract)
A new porcine suspension cell line (PBG.PK-21) provides efficient production for influenza and yellow fever vaccine viruses, Gwendal Gränicher, Yvonne Genzel, Udo Reichl, Katrin John, Volker Sandig, and Alexander Karlas (Abstract)
HILIC-LC/MS method for non-derivatized amino acid analysis in spent media, Hari Kosanam and Kristin Valente (Abstract)
Process development of chromatography-based purification on pandemic influenza virus-like particle based vaccines, Hiachun Lai, Min-Shi Lee, Alan Yung-Chih Hu, and Ting-Hui Lin (Abstract)
Δπ=0 reverse osmosis enriches a high osmotic pressure solution from a low-titre fermentation broth to a saturated solution or salt form using RO and NF membranes, Ho Nam Chang, Kyeong Rok Choi, and Mi Hyang Sun (Abstract)
Upstream process intensification using Viral Sensitizer technology, Jean-Simon Diallo (Abstract)
Molecular understanding of the serum antibody repertoires after seasonal influenza vaccination among different age cohorts, Jiwon Jung, Jiwon Le, Andrew P. Horton, Daniel R. Boutz, Jonathan R. McDaniel, Greg King, Yuri Tanno, Gregory C. Ippolito, George Georgiou, Daechan Park, Ted M. Ross, Sophia Mundle, Ray Oomen, Harry Kleanthous, and Simon Delagrave (Abstract)
Formulation development of a recombinant protein based non-replicating rotavirus (NRRV) vaccine candidate: Antigen-adjuvant-preservative interactions, John M. Hickey, Sangeeta B. Joshi, David B. Volkin, John M. Hickey, David McAdams, Jessica White, Robert Sitrin, Dexiang Chen, and Stanley Cryz (Abstract)
Disruptive micro-facility for affordable vaccine manufacturing, José Castillo (Abstract and Presentation)